Foundation Fighting Blindness, Inc. has reported a significant stock transaction involving its subsidiary, the Foundation Fighting Blindness Retinal Degeneration Fund. This event, filed with the SEC, underscores the company's ongoing efforts to manage its investments strategically.
Foundation Fighting Blindness, Inc. is incorporated in Maryland and operates in the pharmaceutical preparations sector. The company is focused on advancing research and treatments for retinal degenerative diseases. Its recent filings include a Form 4 submitted on October 2, 2026, detailing transactions related to its stock holdings.
The recent filing indicates that the Foundation Fighting Blindness Retinal Degeneration Fund disposed of 556,000 shares of common stock on September 30, 2026. The shares were sold at a weighted average price of $4.9568, with prices ranging from $4.95 to $5.29. Following this transaction, the fund retains ownership of 3,236,171 shares.
This transaction may impact stakeholders, including investors and board members, as it reflects the strategic decisions made by the organization. Notably, the filing mentions that Foundation Fighting Blindness, Inc. is the sole member of the Foundation Fighting Blindness Retinal Degeneration Fund, which gives it beneficial ownership of the securities held by the fund.
What's next for Foundation Fighting Blindness remains unclear, as the filing does not specify any forthcoming actions or additional filings.